Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New coronavirus rbd specific monoclonal antibody and its application

A monoclonal antibody and specific technology, applied in the direction of antibodies, applications, antiviral agents, etc., can solve the problem of limited virus blocking effect, achieve the effect of improving specific binding ability and wide application value

Active Publication Date: 2022-06-21
CHONGQING MEDICAL UNIVERSITY +1
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The Chinese invention patent application with the application publication number CN111303280A discloses a fully human monoclonal antibody with high neutralizing activity against SARS-CoV-2. The above patent provides a fully human monoclonal antibody whose recognition region is the S1 non-RBD region. However, since the new coronavirus invades the host cell through RBD binding to ACE2 of the host cell, the fully human monoclonal antibody obtained in the above patent has limited blocking effect on the virus, and the above patent obtains antibody cDNA by labeling plasma cells, but Compared with plasma cells, memory B cells respond quickly after activation, so memory B cells can trigger a faster and stronger humoral immune response than the initial response, while plasma cells trigger a limited humoral immune response

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New coronavirus rbd specific monoclonal antibody and its application
  • New coronavirus rbd specific monoclonal antibody and its application
  • New coronavirus rbd specific monoclonal antibody and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] This example provides a novel coronavirus RBD-specific monoclonal antibody, the amino acid sequence of the heavy chain is shown in SEQ ID NO: 1; the amino acid sequence of the light chain is shown in SEQ ID NO: 2.

[0022] This embodiment also provides the application of the above-mentioned novel coronavirus RBD-specific monoclonal antibody in the preparation of reagents or drugs for detecting or diagnosing SARS-CoV-2.

[0023] In actual production, the RBD-specific monoclonal antibodies obtained in this example can be used to prepare nucleic acid molecules, or to prepare expression cassettes, recombinant vectors, recombinant bacteria or transgenic cell lines containing the nucleic acid molecules, or to prepare pharmaceutical compositions, the pharmaceutical combination The substance includes the above-mentioned novel coronavirus RBD-specific monoclonal antibody and a pharmaceutically acceptable excipient, diluent or carrier.

[0024] In application, this example obtain...

Embodiment 2-20

[0026] The difference between Example 2-20 and Example 1 is that the amino acid sequences of RBD-specific monoclonal antibodies are different, and the amino acid sequences of Example 2-20 are shown in the following table:

[0027] test group heavy chain amino acid sequence light chain amino acid sequence Example 1 - CQTS113 SEQ ID NO: 1 SEQ ID NO: 2 Example 2 - CQTS114 SEQ ID NO: 3 SEQ ID NO: 4 Example 3 - CQTS115 SEQ ID NO: 5 SEQ ID NO: 6 Example 4 - CQTS116 SEQ ID NO: 7 SEQ ID NO: 8 Example 5 - CQTS117 SEQ ID NO: 9 SEQ ID NO: 10 Example 6 - CQTS118 SEQ ID NO: 11 SEQ ID NO: 12 Example 7 - CQTS119 SEQ ID NO: 13 SEQ ID NO: 14 Example 8 - CQTS120 SEQ ID NO: 15 SEQ ID NO: 16 Example 9 - CQTS121 SEQ ID NO: 17 SEQ ID NO: 18 Example 10 - CQTS122 SEQ ID NO: 19 SEQ ID NO: 20 Example 11 - CQTS123 SEQ ID NO: 21 SEQ ID NO: 22 Example 12 - CQTS124 SEQ ID NO: 23 SEQ ID NO:...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of monoclonal antibodies, and specifically discloses a novel coronavirus RBD-specific monoclonal antibody and the application of the above-mentioned novel coronavirus RBD-specific monoclonal antibody. The present invention has important scientific significance and application prospects for the prevention, clinical treatment and research and development of diagnostic reagents for diseases caused by the novel coronavirus SARS-CoV-2.

Description

technical field [0001] The invention belongs to the technical field of monoclonal antibodies, and in particular relates to novel coronavirus RBD-specific monoclonal antibodies and applications. Background technique [0002] Antibodies are immunoglobulin molecules composed of four polypeptide chains, including two heavy chains (H chains) and two light chains (L chains). The H chain consists of a heavy chain variable region (VH) and a heavy chain constant region, and the heavy chain constant region consists of three regions CH1, CH2 and CH3. The L chain is composed of the L chain variable region (VL) and the light chain constant region, and the light chain constant region is composed of the CL region. VH and VL can be further divided into hypervariable regions called complementarity determining regions (CDRs) and alternately conserved regions called framework regions (FRs). [0003] Current research has found that the new coronavirus (SARS-CoV-2) has four main structural pro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/10C12N15/13G01N33/577G01N33/569A61K39/42A61P31/14
CPCC07K16/10G01N33/577G01N33/56983A61P31/14C07K2317/56G01N2333/165C12N15/85C12N5/0686A61P11/00C12N2800/107C12N2510/00A61K2039/505Y02A50/30
Inventor 金艾顺韩晓建胡超王应明李婷婷王建为李胜龙黄晶晶
Owner CHONGQING MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com